Purpose High mammographic density (MD) is a strong risk factor for breast cancer. Chronic inflammation may be related to breast cancer risk through a mechanism involving the percent of breast area that is dense (percent MD). Longitudinal assessments, however, are lacking and thus were constructed to evaluate the relationship between chronic inflammation and percent MD. Methods We evaluated whether elevated ([3 mg/L) high-sensitivity C-reactive protein (hsCRP), a biomarker of inflammation, was associated with change in percent MD among 653 women aged 42-52 years at baseline in the Study of Women's Health Across the Nation, a longitudinal study of midlife women. We used a mixed model to analyze data from an average of 4.7 mammograms per woman collected during an average follow-up of 4.9 years (SD = 1.47).
tissue [3] . High percent MD is a strong risk factor for breast cancer, conferring a four-to-six-fold increase in risk of women with 60-75 % MD compared to those with no or low percent MD [4] . Percent MD may be a marker of breast cancer risk [9, 10] . Moreover, percent MD declines with age [11] [12] [13] ; thus, the longitudinal study of factors related to the rate of change in percent MD may provide more detail about the relationship than using percent MD at onetime point [14] . Chronic inflammation results in excess cell proliferation and the activation of a series of cellular actions, resulting in the induction of DNA damage, so that prolonged inflammation can lead to initiated cells, tumor growth, metastatic progression, and immunosuppression [15, 16] .
CRP, produced by the liver when inflammation or infection occurs, is an established biomarker of both acute and chronic inflammation [17] [18] [19] [20] [21] [22] [23] . Many cancer cases occur at the sites of chronic inflammation [24] , and circulating levels of CRP may be increased in some cancer patients [20] . Elevated high-sensitivity CRP (hsCRP) has also been related to prevalent cancer and increased risk of future cancer in healthy populations [25] . CRP is a fairly stable biomarker and has little diurnal variation [26, 27] . Breast carcinogenesis may be related to a mechanism involving both chronic inflammation, reflected by elevated circulating levels of CRP, and estrogen pathways (the latter also including percent MD) [20, [28] [29] [30] .
Epidemiologic study results have been inconsistent, with some supporting a positive association between CRP and breast cancer risk [21, 24, [31] [32] [33] [34] [35] [36] , while others have reported no association [25, [37] [38] [39] [40] . One cross-sectional study reported a nonsignificant negative association between CRP and percent MD in healthy postmenopausal women [41] . A longitudinal analysis of changes in CRP and percent MD is needed to understand better the relationship between inflammation and breast cancer risk.
We undertook a novel longitudinal investigation of the relation between high-sensitivity CRP (hsCRP) and changes over 6 years in percent MD among a midlife multiracial/ethnic sample of women. The aims of the present analyses were to assess whether baseline and time-varying elevated hsCRP levels were associated with change in percent MD and whether these associations were affected by use of nonsteroidal anti-inflammatory drugs (NSAIDs) or varied by race/ethnicity.
Materials and methods

SWAN study sample
The Study of Women's Health Across the Nation (SWAN) is a seven-site, community-based, longitudinal cohort study designed to investigate the biological and psychosocial characteristics of the menopausal transition among a racially/ethnically and socioeconomically diverse cohort of women, who at baseline were aged 42-52 years, reported having had a menstrual period in the prior 3 months, had an intact uterus and at least one ovary, and were not using exogenous hormones within the 3 months prior to the recruitment [42] . One minority sample was selected at each site in addition to a Caucasian sample. SWAN recruited and enrolled 3,302 women at baseline or 50 % of total eligible women; 935 were African-American (Boston, Chicago, Detroit, Pittsburgh); 1,550 were Caucasian (all sites); 250 were Chinese (Oakland); 281 were Japanese (Los Angeles), and 286 were Hispanic (Newark). SWAN participants have been evaluated at annual in-person visits since 1996 to obtain information on demographic, medical and reproductive history and events, anthropometrics, medication use, and serum and urine biomarkers of endocrine function, lipids, glucose, inflammation, and bone turnover.
Both the SWAN core study and the MD substudy protocols were approved by the institutional review boards of all participating institutions. All participating women provided written informed consent.
Mammographic density substudy
Three SWAN sites participated in the MD ancillary study: the University of California, Davis-Kaiser (Oakland), the University of California, Los Angeles (Los Angeles), and the University of Pittsburgh (Pittsburgh). Mammograms taken as part of routine medical care were obtained for women in this substudy [43] . For each woman, the ''index mammogram'' was the first mammogram that either followed a SWAN visit or preceded it by no more than 1 month. The SWAN visit closest to the date of this index mammogram was considered the index SWAN visit for this analysis. Mammograms that were acquired more than 1 month prior to the start of SWAN were excluded from analyses. Follow-up mammograms (i.e., mammograms after the index mammogram) were linked with later SWAN visits using the same criteria. The interval between the mammogram and corresponding SWAN visit averaged 0.41 years after the visit (standard deviation = 0.30 years), a sufficiently small interval to minimize the likelihood of major changes in hsCRP or confounders during this time. Of the 1,248 women available at the three SWAN sites at the time of enrollment into the substudy, 85 % agreed to participate. Of those who participated, 1,005 women had at least one eligible mammogram assessed for percent MD. Only women who were pre-or early perimenopausal at baseline and who had at least one follow-up mammogram were included. Women were excluded from this analysis if they had cancer at any time during the study. In total, 801 women were pre-or early perimenopausal at baseline. After excluding those women who did not have two completed mammograms during SWAN's follow-up, a total of 653 women remained for these analyses.
Quantitative assessment of mammograms was made by Martine Salane, an established expert in measuring MD [44] . Ms. Salane's measurements have been highly correlated with computer-assisted MD measurements (r = 0.90) [45] . A compensating polar planimeter (LASICO, Los Angeles, CA) was used to calculate the radio-dense area (in cm 2 ) of the breast tissue and the total area of the breast [43] . Percent MD was calculated by dividing the dense breast area by the total area of the breast and multiplying by 100.
High-sensitivity CRP (hsCRP) assessment
The SWAN protocol included an annual blood draw after a minimum 10-h fast, which was used to measure hsCRP from baseline to visit 6 (except visit 2). HsCRP was assayed using an ultrasensitive immunoephelometric method (Dade-Behring, Marburg, Germany). Because hsCRP was not measured at visit 2, the average of the two closest hsCRP measures was used as the hsCRP value for that visit. This approach was used, because for some women, the index or a follow-up mammogram was closest to visit 2, and an hsCRP value corresponding to that visit was needed for inclusion in the analyses, but hsCRP was not measured in visit 2, so it was imputed from the average of the two visits closest to visit 2. No meaningful differences were observed in the final results when the analyses were repeated without the imputed hsCRP value for visit 2 (data not shown). Details of the specimen collection and hsCRP assay have been published [46] . Although hsCRP level is a continuous variable, a cutoff for elevated hsCRP has been established for clinical use [47] and was used to categorize hsCRP into elevated ([3mg/L) and non-elevated (B3 mg/L) for analyses of both baseline and hsCRP levels over time.
Covariates
Time-invariant covariates obtained from the index SWAN visits were evaluated as potential confounders in the analyses. Based on the literature, the following variables were of interest: annual household income (\$50,000, $50,000-74,000, C$75,000), age at menarche (in years), family history of breast cancer (yes/no based on first-and second-degree female family members who had breast cancer), race/ethnicity (Non-Hispanic Caucasian, AfricanAmerican, Chinese, and Japanese) [43] , parity (number of births), prior oral contraceptive use at baseline (yes/no), and education (high school or less, some college, and college and more). Because of the SWAN study design, combined information about race/ethnicity and recruitment site was categorized and used in the analyses [6] . The following variables were also considered potential confounders: use of hormone therapy (yes/no), baseline menopausal status (premenopausal or early perimenopausal), physical activity score, frequency of alcohol consumption (none, \1 drink per week, 1-7 drinks per week, and [7 drinks per week), vitamin use (yes/no), active and passive smoke exposure (never smoker/no second hand smoking (SHS), never smoker/with SHS, former smoker/no SHS, former smoker/with SHS and current smoker [49] ), and comorbidities (yes/no) from the index SWAN visit. Physical activity was classified according to the Kaiser Permanente Activity Score [48] , which includes physical activity in mutually exclusive domains of sports/exercise, household/caregiving, occupational, and daily routine [14, 48, 49] .
Two time-varying covariates were of particular interest: BMI and menopausal status. In addition to the baseline values, a variable for change since the index SWAN visit was created for each of these variables. The value of BMI for a woman changed for each SWAN visit linked to a mammogram and was defined as the difference between the value at that SWAN visit and the value from the index SWAN visit. For menopausal status, the change from baseline was categorized as: (1) no change in menopausal status; (2) pre-to early perimenopausal; (3) pre-to late perimenopausal; (4) early to late perimenopausal; (5) preto naturally postmenopausal; (6) early peri-to naturally postmenopausal; and (7) change to no periods resulting from surgery or indetermination due to hormone use (combining surgery and hormone use because their individual numbers were relatively small, the final menstrual period could not be determined in most cases, and many women who had hysterectomies used hormones so that the effects could not be separated). In addition, a variable measured the time in years from the index to each subsequent mammogram.
Use of NSAIDs was obtained at each SWAN visit in the interviewer-administered questionnaire. Women were asked about both prescribed and ''regularly used'' over-thecounter medications that were taken ''in the last month'' (at the baseline visit) or ''since your last visit'' (at each followup visit). Regular use was defined as use two or more times per week during the previous month (at baseline), or during any month since the previous visit (at each follow-up visit). Separately for prescription and nonprescription medications, women were asked to name the medication taken with prompting by symptom (e.g., ''for pain including headaches and arthritis''), counter pills or medications that you have taken, that I haven't asked you about?'').
Statistical analyses
All analyses were performed using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). The primary objective of this analysis was to assess the association between hsCRP levels and change in percent MD.
Mixed models were used to examine the association between the index hsCRP status and change in percent MD. These models included factors related to change in percent MD and random intercepts and slopes to account for between-person variability in the starting level and change over time. Model assumptions of linear change, normality, and constant variance of the residuals and bivariate normality of the random effects were checked and were met by the data.
Model building strategies were the same for all outcomes to evaluate the hypotheses of interest. We began with a simple unadjusted model that included categorized hsCRP at the index visit, time, and the interaction between these two (Model 1). Then, we evaluated potential confounders by adding one variable at a time as a main effect and an interaction with time to that simple model and if the coefficient for elevated hsCRP or the interaction of hsCRP and time changed by more than 10 % when a single variable was added, then that variable was included in an adjusted model as either a main effect and interaction with time or just as a main effect. We constructed an adjusted model by adding all confounders identified in the previous step to the simple model.
Next, interactions between time and two time-varying variables for change in BMI and in menopausal status were added to the adjusted model to construct a final adjusted model to assess the associations of these variables with change in the outcome and whether the association between elevated hsCRP level and change in percent MD was the same with the inclusion of these interactions. Because BMI has been strongly associated with percent MD [43] , we constructed models with (Model 2) and without BMI (Model 3). Finally, models were repeated using hsCRP status at each visit as a time-varying variable to reflect better a woman's status over time.
Additional analyses were performed to investigate the association of: 1) elevated hsCRP level with change in percent MD in consistent nonusers of NSAIDs and 2) hsCRP level with dense and non-dense area. Analyses of the association between continuous hsCRP level and change in percent MD and the association of frequently elevated hsCRP (hsCRP [ 3 mg/L for more than half of all visits) with change in percent MD were also conducted.
Results
Approximately 20 % of women had elevated hsCRP at the index visit (Table 1) . Most women were aged 45-49 years (58 %), had normal BMI 18.5-24.9 kg/m 2 (55 %), were non-Hispanic Caucasian (50 %), had no comorbidities (73 %), had age at menarche of 11-15 years (83 %), and were nonusers of NSAIDs (74 %). In addition, 45 % were never smokers with no exposure to second hand smoke; 37 % were not alcohol drinkers; and 38 % had a physical activity score more than 8.5 (the highest tertile). Women who were obese or African-American, moderately physically active, had comorbidities or early age at menarche, and used NSAIDs were more likely to have elevated hsCRP. The mean percent MD at baseline was 44 % (SD = 20.0 %). The average number of mammograms per woman was 4.7 (SD = 1.73; range 2-9) over an average of 4.9 years (SD = 1.47; range 0.92-8.08).
In women with non-elevated hsCRP at baseline, mean percent MD was higher (47 %), compared with women who had elevated hsCRP (31 %) (p \ 0.001) (Fig. 1a) . On average, percent MD declined 1.1 percent (SE = 0.06) per year. The percent MD for women with elevated hsCRP at baseline declined at a 0.44 percentage point (95 % CI 0.14, 0.73) slower rate than those without elevated hsCRP for an overall average rate of decline of 0.73 percent each year in the unadjusted model (Model 1, Table 2 ). In the adjusted model, the direction of the association of change in percent MD with elevated baseline hsCRP was the same but not significant (b = 0.37, 95 % CI -0.09, 0.84) ( Fig. 1b ; Model 2, Table 2 ). This association became significant when BMI was excluded from the model, with a 0.88 percentage point (95 % CI 0.44, 1.31) slower decline in percent MD associated with elevated hsCRP and an overall average rate of decline 1.99 percentage points each year (Table 2, Model 3). A one-unit increase in change in BMI over time was associated with a 0.13 percentage point faster decline in percent MD per year (SE = 0.03, p \ 0.001; Model 2, Table 2 ). The association between baseline hsCRP status and change in MD did not differ significantly by race/ethnicity (data not shown).
Women could have had hsCRP measurements at a total of 4 visits during follow-up in the MD substudy. The average number of visits with hsCRP measurement was 2.5. Women who had elevated hsCRP at over half of the visits did not differ in change in percent MD from women whose hsCRP was less frequently or never elevated (b = 0.39, 95 % CI -0.04, 0.83). Using continuous hsCRP level in place of elevated hsCRP, significant associations between increasing baseline hsCRP levels and slower decline in percent MD were found in an unadjusted model (p = 0.01) and when BMI was not included in the adjusted model (p = 0.006). When using hsCRP as a time-varying predictor, hsCRP was significantly associated with percent MD in both unadjusted and adjusted models (Table 3) . At any point in time, women with elevated hsCRP had a 0.39 percentage point (95 % CI 0.12, 0.66) slower rate of decline in percent MD than those with normal hsCRP for an overall average rate of decline of 0.84 percentage point each year in the unadjusted model (Model 1, Table 3 ). In the adjusted model that included BMI and change in BMI, women who had elevated hsCRP levels at any time point had a 0.40 percentage point (95 % CI 0.07, 0.73) slower rate of decline in percent MD than those with normal hsCRP levels ( Fig. 1c ; Model 2, Table 3 ). In the adjusted model that did not include BMI, a 0.62 percentage point slower rate of decline (95 % CI 0.30, 0.94) was observed for those with elevated hsCRP levels over time with an overall average rate of decline of 2.19 percentage points each year (Model 3, Table 3 ).
At any time point, women with elevated hsCRP also experienced a 1 % slower increase in non-dense breast tissue In analyses restricted to women who were consistent nonusers of NSAIDs across all annual visits up to visit 6 (N = 240), no significant association was seen between elevated hsCRP level at baseline (b = -0.008, SE = 0.56, p = 0.98) or hsCRP status over time (b = -0.03, SE = 0.31, p = 0.93) and change in percent MD. We also did not observe a statistically significant association between baseline hsCRP and change in MD in any racial/ ethnic subgroup, baseline menopausal status subgroup, or in any BMI subgroup (data not shown).
Discussion
In our community-based, multiracial/ethnic sample of 653 midlife women, we observed that elevated hsCRP levels b Fig. 1 over time were statistically significantly associated with a slower decrease in percent MD in unadjusted and adjusted models (with and without BMI). We identified only one prior study, which was cross-sectional [41] , that reported a significant negative association between continuous CRP levels and age-adjusted percent MD in healthy postmenopausal women; this relation was attenuated and nonsignificant when adjusted for BMI. Our study, in contrast, was longitudinal, a benefit over the cross-sectional design. In addition, we examined women who were pre-or early perimenopause at baseline, which permitted us to examine changes in percent MD before women were postmenopausal and at a time when circulating hormones were changing [50, 51] and might thus be a potentially critical window for inflammation [52, 53] ; our results suggested that the relation of hsCRP to percent MD began earlier, i.e., before menopause, in the menopausal transition or earlier.
We also examined the relation of elevated hsCRP ([3 mg/L), as both baseline and time-varying, providing more information about inflammation than the one-time assessment.
A few studies have investigated the relationship between CRP and breast cancer risk, but the results have been inconsistent. A recent meta-analysis of prospective studies by Heikkila et al. [21] showed a slight, but non-statistically significant, increased breast cancer risk associated with higher levels of CRP. A few studies [31, 32, 37] have found a nonsignificant relation of elevated CRP to breast cancer risk, while the Rotterdam cohort study indicated a statistically significant 28 % increase in breast cancer risk of every one-unit increase in CRP [34] . Further, mammographic dense volume, a measure of fibroglandular tissue, has been negatively correlated with C-reactive protein (CRP) [54] .
Inflammation results in excess cell proliferation [15] . In addition, CRP, an inflammation cytokine, decreases when COX-2 is inhibited [55] . COX-2 overexpression results in an increase in prostaglandins, especially prostaglandin E2 [56, 57] , which increases aromatase gene expression and thus stimulates local estrogen production [58] , which may also increase mammographic density [59] . Thus, our finding that time-varying elevated hsCRP was associated with a slower decline in percent MD is consistent with these hormonal changes related to inflammation.
Our study had some limitations to consider when interpreting our results. First, because women in our cohort were pre-or early perimenopausal at baseline and were followed only for 6 years, and we lacked sufficient numbers of women to evaluate the relationship of elevated hsCRP to decline in percent MD in postmenopausal women. Second, because NSAID use is related to inflammation, we included NSAID use in an adjusted model, and The beta coefficient of time reflects the average annual change in percent MD for a reference woman. In Model 1, the reference is a woman with non-elevated hsCRP level (B3 mg/ml). In Model 2, the reference is premenopausal with no change in menopausal status, Caucasian, nondrinker, non-smoker, non-vitamin user from the Pittsburgh site who has no comorbidities and average baseline level of BMI and no change in BMI. In Model 3, the reference is premenopausal with no change in menopausal status, Caucasian, nondrinker, non-smoker, non-vitamin user from the Pittsburgh site who has no comorbidities 2 The beta coefficient of elevated baseline hsCRP 9 time reflects the average difference in annual change in percent MD between baseline nonelevated hsCRP level (B3 mg/ml) and elevated hsCRP level ([3 mg/ml). For example, in Model 1, the unadjusted model, percent MD in women with elevated hsCRP levels decreased 0.44 percentage points per year less than women with non-elevated hsCRP level, for an average rate of change of -0.73 (-1.17 ? 0. 44) no substantial change was observed in the relation of elevated hsCRP to reduced decline in percent MD. However, we may have had some misclassification of information of NSAID use due to recall, particularly of the nonprescription forms of this medication, and to short and variable durations of use, which may at least partially explain the lack of an observed effect. Our study also had many strengths. First, this is the first study of which we are aware to investigate the association of change in percent MD with elevated hsCRP using objective measures. Second, this study was a longitudinal cohort design and had over 6 years of data on percent MD in a large multiracial/ethnic sample of midlife women, so that the longitudinal relation of elevated baseline hsCRP to change in percent MD could be assessed. Third, SWAN is a multiracial/ethnic, community-based, cohort; therefore, the results of this study are likely to be generalizable to pre-and perimenopausal US women. Fourth, all data collection was performed by well-trained staff, all using the same standard protocol so that quality control was high. Fifth, the mammograms were read by only one specialist who had very high accuracy and who was masked to hsCRP levels, thus reducing the potential for differential misclassification.
BMI appears to play an important role in the association of CRP with MD because BMI is strongly correlated with MD [31, 60, 61] and strongly correlated with CRP [35, 62] . In some studies [37, 41] , and in our initial analyses, a single measure of CRP at baseline had no relation to MD when also accounting for BMI. While this may lead to the conclusion that inflammation does not independently affect breast cancer risk through a pathway that includes MD, in our longitudinal analyses examining time-varying elevated hsCRP (a more informative approach because it more directly links the hsCRP status over time with percent MD decline and takes into consideration that a woman's hsCRP level at baseline may not be indicative of her inflammation process over time), the association between elevated hsCRP over time and change in percent MD remained statistically significant even after adjusting for BMI. This result suggests that inflammation, a potential risk factor for breast cancer, may be related to a slower decline of MD over time. However, this finding requires verification in future studies because the relation of elevated hsCRP over time to a slower decline in percent MD may have been due to such women starting with a lower percent MD and thus having less ability to be much further reduced (i.e., a floor effect); 36 % of those with elevated 1 The beta coefficient of time reflects the average annual change in percent MD for a reference woman. In Model 1, the reference is a woman with non-elevated hsCRP level (B3 mg/ml). In Model 2, the reference is premenopausal with no change in menopausal status Caucasian, nondrinker, non-smoker, non-vitamin user from the Pittsburgh site who has no comorbidities and average baseline level of BMI and no change in BMI. In Model 3, the reference is premenopausal with no change in menopausal status, Caucasian, nondrinker, non-smoker, non-vitamin user from the Pittsburgh site who has no comorbidities 2 The beta coefficient of time-varying elevated hsCRP 9 time reflects the average difference in annual change in percent MD between nonelevated hsCRP level (B3 mg/ml) and elevated hsCRP level ( hsCRP at baseline started with a percent MD less than 20, while only 16 % of those with non-elevated hsCRP at baseline had a percent MD less than 20. The higher proportion of women with low percent MD in those with elevated baseline CRP could at least partially explain the reduced rate of decline in percent MD in this group after adjustment for confounding variables, but the significant differences in rates of age-related decline in percent MD could also suggest that inflammation may play a role in reducing the rate of agerelated decline in percent MD, a suggestion that requires further testing in larger longitudinal studies. Further studies should explore the complex processes of inflammation and change in MD and whether BMI and inflammation are on the same causal pathway of breast carcinogenesis. To date, this is one of the largest cohort studies with longer follow-up and more mammogram and hsCRP measurements used to assess the association between hsCRP and percent MD. This is the first study of which we are aware that considered hsCRP status both at baseline and as a time-varying independent predictor of change in percent MD over time. We also controlled for many confounders in our analyses, thus reducing the chance for biased results due to residual confounding. In conclusion, our results provide limited support for the hypothesis that inflammation may play an important role in change in percent MD with age, but this role remains uncertain due to our finding that while higher baseline hsCRP was associated with lower percent MD, elevated hsCRP levels over time were associated with a slower decline in percent MD over time. Few, if any, studies have examined the association between elevated hsCRP over time and change in MD, and further study of this association is needed to clarify the role of inflammation in breast cancer, and whether this association acts through or is reflected by mammographic density.
